Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: An evolution-based strategy.
CONCLUSION: Mathematical models can integrate evolutionary dynamics into multidrug cancer clinical trials. This has the potential to improve outcomes and to develop clinical trials in which these mathematical models are also used to estimate the mechanism(s) of treatment failure and explore alternative strategies to improve outcomes in future trials.
PMID: 30992299 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: West JB, Dinh MN, Brown JS, Zhang J, Anderson AR, Gatenby RA Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Docetaxel | Multidrug Resistance | Prostate Cancer | Taxotere | Toxicology